PE20221339A1 - Inhibidores de parp1 - Google Patents

Inhibidores de parp1

Info

Publication number
PE20221339A1
PE20221339A1 PE2022000086A PE2022000086A PE20221339A1 PE 20221339 A1 PE20221339 A1 PE 20221339A1 PE 2022000086 A PE2022000086 A PE 2022000086A PE 2022000086 A PE2022000086 A PE 2022000086A PE 20221339 A1 PE20221339 A1 PE 20221339A1
Authority
PE
Peru
Prior art keywords
oxo
parp1 inhibitors
naftiridin
parp1
inhibitors
Prior art date
Application number
PE2022000086A
Other languages
English (en)
Inventor
Martin John Packer
Jeffrey Wallace Johannes
Sudhir Mahadeo Hande
Sebastien Louis Degorce
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20221339A1 publication Critical patent/PE20221339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE (2-OXO-1H-1,6-NAFTIRIDIN-7-IL; 6-OXO-5H-1,5-NAFTIRIDIN-3IL o 3-OXO-4H-QUINOXALIN-6-IL)-METIL-PIPERAZIN-1IL-N-PIRIDIN-2-CARBOXAMIDA DE FORMULA (I) DONDE X1, X2 y X3 SE SELECCIONAN DE N y C; R1, R2 y R3 SON ALQUILO C1-4, ENTRE OTROS O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, DONDE DICHOS COMPUESTOS SON INHIBIDORES DE PARP1.
PE2022000086A 2019-07-19 2020-07-17 Inhibidores de parp1 PE20221339A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962876065P 2019-07-19 2019-07-19
PCT/EP2020/070306 WO2021013735A1 (en) 2019-07-19 2020-07-17 Parp1 inhibitors

Publications (1)

Publication Number Publication Date
PE20221339A1 true PE20221339A1 (es) 2022-09-13

Family

ID=71728735

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000086A PE20221339A1 (es) 2019-07-19 2020-07-17 Inhibidores de parp1

Country Status (20)

Country Link
US (2) US11325906B2 (es)
EP (1) EP3999506A1 (es)
JP (1) JP2022541483A (es)
KR (1) KR20220035941A (es)
CN (1) CN114144413A (es)
AR (1) AR119424A1 (es)
AU (1) AU2020318599B2 (es)
BR (1) BR112022000534A2 (es)
CA (1) CA3145644A1 (es)
CL (1) CL2022000110A1 (es)
CO (1) CO2022001590A2 (es)
CR (1) CR20220070A (es)
DO (1) DOP2022000006A (es)
EC (1) ECSP22012826A (es)
IL (1) IL289534A (es)
JO (1) JOP20220008A1 (es)
MX (1) MX2022000711A (es)
PE (1) PE20221339A1 (es)
UY (1) UY38793A (es)
WO (1) WO2021013735A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220008869A (ko) 2019-05-14 2022-01-21 누베이션 바이오 인크. 항암 핵 호르몬 수용체-표적화 화합물
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
TW202222350A (zh) 2020-10-09 2022-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及parp1選擇性抑制劑之組合
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20230172550A (ko) 2021-04-19 2023-12-22 신테라, 인크. Parp1 저해제 및 이의 용도
AU2022261011A1 (en) * 2021-04-22 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
CN115702156A (zh) * 2021-04-23 2023-02-14 南京明德新药研发有限公司 吡啶酰胺类化合物
KR20240005756A (ko) * 2021-04-23 2024-01-12 상하이 한서 바이오메디컬 컴퍼니 리미티드 헤테로사이클릭 유도체 억제제 및 이의 제조방법 및 이의 용도
WO2022222966A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
WO2022222964A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
AU2022276986A1 (en) * 2021-05-18 2023-11-30 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
BR112023022496A2 (pt) 2021-05-24 2024-01-16 Jiangsu Hengrui Pharmaceuticals Co Ltd Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
EP4355334A1 (en) * 2021-06-16 2024-04-24 Repare Therapeutics Inc. Use of atr inhibitors in combination with parp inhibitors for treating cancer
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051807A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 双环衍生物parp抑制剂及其用途
WO2023051812A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
TW202322807A (zh) 2021-10-01 2023-06-16 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
TW202322811A (zh) * 2021-10-22 2023-06-16 大陸商海思科醫藥集團股份有限公司 Parp-1降解劑及其用途
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2023088408A1 (zh) * 2021-11-19 2023-05-25 成都百裕制药股份有限公司 选择性parp1抑制剂及其应用
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023109521A1 (zh) * 2021-12-17 2023-06-22 凯复(苏州)生物医药有限公司 Parp抑制剂、包含其的药物组合物及其用途
WO2023118085A1 (en) * 2021-12-21 2023-06-29 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
TW202332438A (zh) * 2021-12-22 2023-08-16 美商思諾維新醫藥公司 Ｐａｒｐ１抑制劑
WO2023133413A1 (en) * 2022-01-07 2023-07-13 Slap Pharmaceuticals Llc Multicyclic compounds
CN116425744A (zh) * 2022-01-13 2023-07-14 优领医药科技(香港)有限公司 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用
WO2023138541A1 (zh) * 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2023141290A1 (en) 2022-01-21 2023-07-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
WO2023146957A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
WO2023146960A1 (en) * 2022-01-28 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2023165501A1 (zh) * 2022-03-01 2023-09-07 杭州领业医药科技有限公司 Azd5305的晶型及其制备方法和用途
WO2023178035A1 (en) * 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023194530A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194525A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
EP4355749A1 (en) 2022-04-28 2024-04-24 Xinthera, Inc. Tricyclic parp1 inhibitors and uses thereof
WO2023207283A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Compounds as parp1 inhibitiors
WO2023217045A1 (zh) * 2022-05-07 2023-11-16 南京明德新药研发有限公司 选择性抑制parp1的氟代喹喔啉酮衍生物
WO2023227052A1 (zh) * 2022-05-25 2023-11-30 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer
WO2024012572A1 (zh) * 2022-07-14 2024-01-18 西藏海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024067691A1 (zh) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
WO2024067694A1 (zh) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
WO2024077137A1 (en) * 2022-10-06 2024-04-11 Xinthera, Inc. Crystalline forms of a parp1 inhibitor
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
WO2024083211A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 并杂环类氘代化合物及其用途
CN117917407A (zh) * 2022-10-20 2024-04-23 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
WO2024083204A1 (zh) * 2022-10-21 2024-04-25 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂的盐、晶型及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT705902E (pt) 1994-08-12 2002-05-31 Univ Utah Res Found Gene de susceptibilidade para o cancro da mama e do ovario, ligado a 17q.
AU686004B2 (en) 1994-08-12 1998-01-29 Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
EA009469B1 (ru) 2003-03-12 2007-12-28 Кудос Фармасеутикалс Лимитед Производные фталазинона
EP1687277B1 (en) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
EP1709012B1 (en) 2003-12-05 2015-07-29 Janssen Pharmaceutica NV 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose)polymerase inhibitors
EP1694653B1 (en) 2003-12-10 2016-01-20 Janssen Pharmaceutica NV 6-(hetero-)cyclohexylalkyl substituted 2-quinolinones/2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
MX2007002318A (es) 2004-08-26 2007-04-17 Kudos Pharm Ltd Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
ES2448870T3 (es) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Derivados de quinolina como inhibidores de PARP
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
JP5715625B2 (ja) * 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
DK3312177T3 (da) 2015-06-09 2021-07-05 Onconic Therapeutics Inc Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme

Also Published As

Publication number Publication date
CR20220070A (es) 2022-03-21
MX2022000711A (es) 2022-02-23
AU2020318599B2 (en) 2023-09-07
BR112022000534A2 (pt) 2022-05-10
US20210040084A1 (en) 2021-02-11
AR119424A1 (es) 2021-12-15
KR20220035941A (ko) 2022-03-22
CO2022001590A2 (es) 2022-03-18
TW202116750A (zh) 2021-05-01
US20220227768A1 (en) 2022-07-21
WO2021013735A1 (en) 2021-01-28
UY38793A (es) 2021-02-26
DOP2022000006A (es) 2022-03-15
CA3145644A1 (en) 2021-01-28
AU2020318599A1 (en) 2022-03-10
IL289534A (en) 2022-03-01
JOP20220008A1 (ar) 2023-01-30
CL2022000110A1 (es) 2022-09-20
US11325906B2 (en) 2022-05-10
EP3999506A1 (en) 2022-05-25
CN114144413A (zh) 2022-03-04
JP2022541483A (ja) 2022-09-26
ECSP22012826A (es) 2022-03-31

Similar Documents

Publication Publication Date Title
PE20221339A1 (es) Inhibidores de parp1
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
AR115949A1 (es) Compuestos heterocíclicos
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
UY38057A (es) Inhibidores de sarcómero cardíaco
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
DOP2020000249A (es) N-benzisoxazolilo bencenosulfonamidas como inhibidores de kat
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
PH12017501326A1 (en) Tgf-� inhibitors
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
PE20160180A1 (es) Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos.
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
UY30941A1 (es) Inhibidores de serina proteasas
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
CL2021001461A1 (es) Moduladores de trex1
EA202193015A1 (ru) Ингибиторы cdk
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met